The Biomarkers Consortium: Practice and Pitfalls of Open-Source Precompetitive Collaboration
Authors:
- 1 May 2010
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 87 (5) , 539-542
Abstract
Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator-activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross-company precompetitive collaboration is a feasible robust approach to biomarker qualification.Keywords
This publication has 8 references indexed in Scilit:
- Novel consortium to address shortfall in innovative medicines for psychiatric disordersNature Reviews Drug Discovery, 2009
- Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple SponsorsClinical Pharmacology & Therapeutics, 2009
- Open innovation networks between academia and industry: an imperative for breakthrough therapiesNature Medicine, 2009
- Something wiki this way comesNature, 2009
- The State of Innovation in Drug DevelopmentClinical Pharmacology & Therapeutics, 2008
- Obstacles and Opportunities in New Drug DevelopmentClinical Pharmacology & Therapeutics, 2008
- The Biomarkers Consortium: On the Critical Path of Drug DiscoveryClinical Pharmacology & Therapeutics, 2008
- Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New DrugsClinical Pharmacology & Therapeutics, 2007